Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

AZNAstraZenecaRunning, no new patients

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Newly Diagnosed · Advanced Ovarian Cancer · FIGO Stage III-IV · BRCA Mutation · Complete Response · Partial Response · First Line Platinum Chemotherapy

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 3
Patients
450 (final count)
Started
Aug 26, 2013
Main results expected
May 17, 2018
Fully finished
Aug 29, 2028
Results posted
Jul 9, 2019

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Measured over: Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks thereafter until objective radiological disease progression. DCO: 17 May 2018

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT01844986 · record last updated 2025-12-10 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT01844986) ↗